Mechanisms affecting neutrophil migration capacity in breast cancer patients before and after chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 2, 2014, Pages 317-324

  Mendonça, Maria Angélica Oliveira ^a,c   Souto, Fabrício O ^b   Micheli, Douglas C ^a   Alves Filho, José Carlos ^b   Cunha, Fernando Q ^b   Murta, Eddie Fernando C ^a   Tavares Murta, Beatriz M ^a  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Breast cancer; Chemotherapy; CXC receptors; Cytokines; Nitric oxide

Indexed keywords

ANTHRACYCLINE; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE SYSTEM; LEUKOCYTE MIGRATION; MULTIPLE CYCLE TREATMENT; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; SERUM;

ACTINS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL MOVEMENT; CYCLOPHOSPHAMIDE; CYTOKINES; DOXORUBICIN; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKIN-8; LEUKOCYTE DISORDERS; MIDDLE AGED; NEUTROPHILS; NITRIC OXIDE; RECEPTORS, CXCR;

EID: 84896050744     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2348-x     Document Type: Article

References (32)

1. Soehnlein O, Lindbom L (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 10:427-439. doi:10.1038/nri2779
2. Lehrnbecher T, Koehl U, Wittekindt B, Bochennek K, Tramsen L, Klingebiel T, Chanock SJ (2008) Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. Lancet Oncol 9:269-278. doi:10.1016/S1470-2045(08)70071-8 (Pubitemid 351722946)
3. Ribeiro RA, Flores CA, Cunha FQ, Ferreira SH (1991) IL-8 causes in vivo neutrophil migration by a cell-dependent mechanism. Immunology 73:472-477
4. Tavares-Murta BM, Cunha FQ, Ferreira SH (1998) The intravenous administration of tumor necrosis factor alpha, interleukin 8 and macrophage-derived neutrophil chemotactic factor inhibits neutrophil migration by stimulating nitric oxide production. Br J Pharmacol 124:1369-1374. doi:10.1038/sj.bjp.0701965 (Pubitemid 28360558)
5. Niggli V (2003) Signaling to migration in neutrophils: importance of localized pathways. Int J Biochem Cell Biol 35:1619-1638. doi:10.1016/S1357- 2725(03)00144-4
6. Schratl P, Heinemann A (2009) Differential involvement of Ca2+ and actin filament in leukocyte shape change. Pharmacology 83:131-140. doi:10.1159/000186498
7. Fan J, Malik AB (2003) Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors. Nat Med 9:315-321. doi:10.1038/nm832 (Pubitemid 36362787)
8. Richards J, McNally B, Fang X, Caligiuri MA, Zheng P, Liu Y (2008) Tumor growth decreases NK and B cells as well as common lymphoid progenitor. PLoS One 3:e3180. doi:10.1371/journal.pone.0003180
9. Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y (2006) Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood 108:246-252. doi:10.1182/blood-2005-11-4535 (Pubitemid 43990635)
10. Fernandes PC Jr, Garcia CB, Micheli DC, Cunha FQ, Murta EF, Tavares-Murta BM (2007) Circulating neutrophils may play a role in the host response in cervical cancer. Int J Gynecol Cancer 17:1068-1074. doi:10.1111/j.1525-1438. 2007.00922.x
11. Garcia CB, Fernandes PC Jr, Micheli DC, Pereira AHM, Murta EFC, Tavares-Murta BM (2008) Effect of treatment on mononuclear cell migration in cervical cancer patients. Tumori 94:712-717. doi:10.1700/386.4545
12. Micheli DC, Fernandes PC Jr, Cruvinel JCG, Nomelini ID, Murta EFC, Tavares-Murta BM (2012) Circulating cytokines and nitric oxide are involved in the inhibition of neutrophil migration in patients with uterine cervical neoplasia. Clin Med Insights Oncol 6:233-242. doi:10.4137/CMO.S9518
13. Póka R, Szûcs S, Ádány R, Szikszay E (2000) Stage-related superoxide anion production of granulocytes of gynecologic cancer patients. Eur J Obstet Gynecol Reprod Biol 89:55-57. doi:10.1016/S0301-2115(99) 00159-1
14. Mendonça MA, Cunha FQ, Murta EF, Tavares-Murta BM (2006) Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy. Cancer Chemother Pharmacol 57:663-670. doi:10.1007/s00280-005- 0086-4 (Pubitemid 43237852)
15. Schmidt HHHW, Wilke P, Evers B, Bohme E (1989) Ezymatic formation of nitrogen oxides from L-arginine in bovine brain cytosol. Biochem Biophys Res Commun 165:284-291. doi:10.1016/0006-291X(89)91067-X
16. Green LC, Ruiz de Luzuriaga K, Wagner DA, Rand W, Istfan N, Young VR, Tannenbaum SR, Wagner DA et al (1981) Nitrate biosynthesis in man. Proc Natl Acad Sci USA 78:7764-7768
17. Benjamim CF, Ferreira SH, Cunha FQ (2000) Role of nitric oxide in the failure of neutrophil migration in sepsis. J Infect Dis 182:214-223. doi:10.1086/315682 (Pubitemid 30497807)
18. Arraes SM, Freitas MS, da Silva SV, de Paula Neto HA, Alves-Filho JC, Auxiliadora Martins M, Basile-Filho A, Tavares-Murta BM, Barja-Fidalgo C, Cunha FQ (2006) Impaired neutrophil chemotaxis in sepsis associates with GRK expression and inhibition of actin assembly and tyrosine phosphorylation. Blood 108:2906-2913. doi:10.1182/blood-2006-05-024638
19. Finn OJ (2012) Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 23:6-9. doi:10.1093/annonc/mds256
20. Lyon DE, McCain NL, Walter J, Schubert C (2008) Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57:51-58. doi:10.1097/01.NNR.0000280655.58266.6c
21. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25:94-102. doi:10.1016/j.cyto.2003.10.004 (Pubitemid 38096266)
22. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE (2005) Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:981-987. doi:10.1158/1055-9965.EPI-04-0404 (Pubitemid 40478567)
23. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Eel-D Azzam, Khalifa A (2004) Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 37:363-369. doi:10.1016/j.clinbiochem.2004.01.014 (Pubitemid 38490454)
24. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K (1994) Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 56:559-564 (Pubitemid 24348812)
25. Raghuwanshi SK, Su Y, Singh V, Haynes K, Richmond A, Richardson RM (2012) The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. J Immunol 189:2824-2832. doi:10.4049/jimmunol.1201114
26. Rios-Santos F, Alves-Filho JC, Souto FO, Spiller F, Freitas A, Lotufo CM, Soares MB, Dos Santos RR, Teixeira MM, Cunha FQ (2007) Down-regulation of CXCR2 on neutrophils in severe sepsis is mediated by inducible nitric oxide synthase-derived nitric oxide. Am J Respir Crit Care Med 175:490-497. doi:10.1164/rccm.200601-103OC (Pubitemid 46354253)
27. Dincer Y, Akcay T, Tortum OB, Dogusoy G (2006) Nitric oxide and antioxidant defense in patients with gastric cancer. Dig Dis Sci 51:1367-1370. doi:10.1007/s10620-005-9021-0 (Pubitemid 44315803)
28. Grimm EA, Sikora AG, Ekmekcioglu S (2013) Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res. doi:10.1158/1078-0432.CCR-12-1554
29. Sayed-Ahmad MM, Shouman SA, Ramadan LA (2002) Contribution of nitric oxide in doxorubicin-related cytotoxicity in murine tumour model. J Egypt Natl Canc Inst 14:111-116
30. Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, Colado Simão AN, Cecchini AL, Cecchini R (2012) Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 133:89-97. doi:10.1007/s10549-011-1693-x
31. Howard OM, Ben-Baruch A, Oppenheim JJ (1996) Chemokines: progress toward identifying molecular targets for therapeutic agents. Trends Biotechnol 14:46-51. doi:10.1016/0167-7799(96)80920-6 (Pubitemid 26056341)
32. Invernizzi R, Grasso D, Travaglino E, Benatti C, Collovà E, Manzoni M, Livraghi L, Danova M, Riccardi A (2008) Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose-dense chemotherapy. Oncology 75:237-244. doi:10.1159/000164588